{
    "clinical_study": {
        "@rank": "72238", 
        "arm_group": {
            "arm_group_label": "MRIs and PSA Blood Test", 
            "arm_group_type": "Experimental", 
            "description": "Visit 1 (8 weeks after starting ADT): PSA blood test and prostate MRI\nVisit 2 (6 weeks after starting EBRT): PSA blood test and prostate MRI\nVisit 3 (on last day of EBRT): PSA blood test\nVisit 4 (6 months after finishing EBRT): PSA blood test and prostate MRI"
        }, 
        "brief_summary": {
            "textblock": "In this research study, the investigators are trying to determine if there are measurable\n      changes in prostate MRI that will help predict those who will or will not respond to\n      Androgen Deprivation Therapy (ADT) and External Beam Radiation Therapy (EBRT) The first\n      baseline prostate MRI prior to the start of treatment is standard of care. The participant's\n      ADT/EBRT treatment is also standard of care, as advised by their doctor. It is the 3 follow\n      up prostate MRIs during ADT/EBRT treatment, and 4 follow up serum PSA levels that are part\n      of this research study."
        }, 
        "brief_title": "Early Changes In Multiparametric MRI In Prostate Cancer", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "If the participant chooses to take part in this research study, the participant will have 3\n      follow up prostate MRIs during a 6 month time period, while the participant is having their\n      ADT/EBRT treatment. These follow-up prostate MRIs will use a standard imaging protocol\n      without the use of an endorectal coil. The participant will also have a total of 4 blood\n      samples to measure serum PSA. 1-2 mls (just less than \u00bd teaspoon) will be taken for each\n      sample.\n\n      Research Study Plan\n\n        -  Baseline Visit (routine standard of care screening visit): PSA blood test and prostate\n           MRI\n\n        -  Visit 1 (8 weeks after starting ADT): PSA blood test and prostate MRI\n\n        -  Visit 2 (6 weeks after starting EBRT): PSA blood test and prostate MRI\n\n        -  Visit 3 (on last day of EBRT): PSA blood test\n\n        -  Visit 4 (6 months after finishing EBRT): PSA blood test and prostate MRI\n\n      Planned Follow-up: The investigator would like to keep track of the participant's prostate\n      cancer status while they continue to see their doctor at DFCI. The investigators would like\n      to do this by collecting the following data from the participant's medical records, to look\n      at long-term outcome of their ADT/EBRT treatment.\n\n        -  PSA values\n\n        -  Clinical results of your treatment. The investigator will not contact the participant\n           to obtain this information."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult males with unfavorable intermediate- to high-risk localized disease, defined\n             as:\n\n          -  Clinical or radiographic T2b-T4 primary tumor\n\n          -  Gleason score 7-10 in any core\n\n          -  PSA \u2265 10 prior to initiation of therapy\n\n          -  Patients are deemed suitable for therapy with ADT and EBRT.\n\n          -  Subjects must to able to provide informed written consent prior to study entry.\n\n        Exclusion Criteria:\n\n          -  The standard exclusion criteria for MRI exams will apply which include patients with\n             pacemakers, non-compatible intra-cranial vascular clips, inner ear implants, and\n             severe claustrophobia.\n\n          -  Patients who because of age, general medical or psychiatric condition, or physiologic\n             status unrelated to the presence of prostate cancer are unlikely to be candidates for\n             repeat MRIs, or cannot give valid informed consent.\n\n          -  Patients unwilling or unable to undergo the multiparametric MRI exam (non-endorectal\n             coil).\n\n          -  Patients with a history of allergic reaction to latex or Gadolinium containing\n             intravenous contrast agents.\n\n          -  Individuals with renal disease or other contraindications to gadolinium will be\n             excluded.  The BWH standard MRI contrast screening criteria will be used to establish\n             renal status.\n\n          -  Patients who have had prior prostatectomy or prior androgen therapy.\n\n          -  Patients with hip implant or any other metallic implant or device that results in\n             significant distortion of the local magnetic field and compromise of the quality of\n             the multiparametric MRI data."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959542", 
            "org_study_id": "13-343"
        }, 
        "intervention": [
            {
                "arm_group_label": "MRIs and PSA Blood Test", 
                "intervention_name": "MRI", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "MRIs and PSA Blood Test", 
                "description": "Serum PSA will also be subsequently checked on the same day as each follow-up MR is performed, i.e. TP 1, 2 and 3, and right after finishing EBRT. 1-2 mls of blood will be sampled per blood test.", 
                "intervention_name": "PSA Blood Test", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Prostate Cancer", 
        "lastchanged_date": "December 16, 2013", 
        "location": [
            {
                "contact": {
                    "email": "FFENNESSY@PARTNERS.ORG", 
                    "last_name": "Fiona Fennessy, MD, Ph.D", 
                    "phone": "617-632-4785"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Brigham and Women's Hospital"
                }, 
                "investigator": {
                    "last_name": "Fiona Fennessy, MD, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "FFENNESSY@PARTNERS.ORG", 
                    "last_name": "Fiona Fennessy, MD, PhD", 
                    "phone": "617-632-4785"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Fiona Fennessy, MD, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Early Changes in Multiparametric MRI in Response to Neoadjuvant Androgen Deprivation and External Beam Radiation Therapy for Prostate Cancer", 
        "overall_contact": {
            "email": "FFENNESSY@PARTNERS.ORG", 
            "last_name": "Fiona Fennessy, MD, PhD", 
            "phone": "(617) 632-4785"
        }, 
        "overall_contact_backup": {
            "email": "LGREENBERG@PARTNERS.ORG", 
            "last_name": "Louise Greenberg, M.eD", 
            "phone": "(617) 755 6158"
        }, 
        "overall_official": {
            "affiliation": "Dana-Farber Cancer Institute", 
            "last_name": "Fiona Fennessy, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint of this study is whether mpMR parameters measured after 2 months of neoadjuvant ADT therapy (TP1) correlate with nadir PSA post 8-weeks of ADT. In addition, we will determine whether mpMR parameters in areas of tumor (T) in those who fail neoadjuvant ADT (defined as PSA end ADT values >.3 ng/ml) are different to those who respond to ADT (defined as PSA end ADT \u2264.3ng/ml)", 
            "measure": "The primary aim of this study is to explore the feasibility of mpMR as an early imaging biomarker to assess response of intermediate- and high-risk prostate cancer during treatment with neoadjuvant ADT", 
            "safety_issue": "No", 
            "time_frame": "2 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959542"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Dana-Farber Cancer Institute", 
            "investigator_full_name": "Fiona Fennessy", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "A secondary endpoint of this study is whether mpMR parameters measured after 6 weeks of EBRT (TP2) and 8 weeks after completion of EBRT (TP3) correlate with end PSA (defined as PSA level immediately after EBRT treatment). In addition, we will determine whether mpMR parameters in areas of T in those likely to fail combined ADT/EBRT (defined as PSA end values >.5ng/ml) are different to those of responders (PSA end values \u2264.5ng/ml).", 
            "measure": "A secondary aim is to explore the feasibility of mpMR as an imaging biomarker to assess response of bulky localized prostate cancer to combined ADT/EBRT.", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "source": "Dana-Farber Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institutes of Health (NIH)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Dana-Farber Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}